Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.